Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Equity: 2022-2025

Historic Return on Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to -0.60%.

  • Amylyx Pharmaceuticals' Return on Equity rose 54.00% to -0.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.60%, marking a year-over-year increase of 54.00%. This contributed to the annual value of -1.01% for FY2024, which is 113.00% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Return on Equity stood at -0.60% for Q3 2025, which was up 41.24% from -1.01% recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Return on Equity high stood at 0.12% for Q4 2023, and its period low was -2.70% during Q1 2022.
  • For the 3-year period, Amylyx Pharmaceuticals' Return on Equity averaged around -0.63%, with its median value being -0.57% (2024).
  • In the last 5 years, Amylyx Pharmaceuticals' Return on Equity skyrocketed by 227bps in 2023 and then crashed by 178bps in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Return on Equity (Quarterly) stood at -0.82% in 2022, then soared by 94bps to 0.12% in 2023, then plummeted by 178bps to -1.67% in 2024, then soared by 54bps to -0.60% in 2025.
  • Its last three reported values are -0.60% in Q3 2025, -1.01% for Q2 2025, and -1.19% during Q1 2025.